Recruiting NCT03128996
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: RIC regimen, GVHD prophylaxis regimen.
- Who it may be relevant to
- Registry conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders. Basic parameters: 1 Day — 21 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
Overview
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Detailed description
Patients \< 21 years of age with a non-malignant disorder benefited by hematopoietic stem cell transplant will receive a reduced intensity conditioning regimen consisting of hydroxyurea, alemtuzumab, fludarabine, thiotepa, and melphalan.
This will be followed by a familial HLA-mismatched bone marrow transplant. The primary objective is to establish safety and donor cell engraftment at 100 days and 1 year post-transplant.
Interventions
- Drug RIC regimen
Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant - Drug GVHD prophylaxis regimen
Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Day +90: rituximab (375mg/m2 IV once) Patients \>/= 12 yrs - Days +120 to +180: abatacept (IND) monthly (10mg/kg/day IV) Patients \>/= 12 yrs - Days +210 to +390: abatacept (IND) monthly (5mg/kg/day) Patients \<12 yrs - Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
Primary outcome measures
- Donor engraftment [Time frame: 100 days and 1 year post-transplant]
Secondary outcome measures (12)
- Time to neutrophil engraftment [Time frame: 100 days post-transplant]
- Time to platelet engraftment [Time frame: 100 days post-transplant]
- Effect of BMT on pulmonary function [Time frame: 90 days, 1 year, and 2 years post-transplant]
- Effect of BMT on hepatic function [Time frame: 90 days, 180 days, 1 year, and 2 years post-transplant]
- Effect of BMT on neurologic function [Time frame: 90 days, 1 year, and 2 years post-transplant]
- Effect of BMT on cardiac function [Time frame: 90 days, 1 year, and 2 years post-transplant]
- Effect of BMT on renal function [Time frame: 90 days, 180 days, 1 year, and 2 years post-transplant]
- Pharmacokinetics of alemtuzumab [Time frame: days -19, day 0, day +15, and day +30]
- Pharmacokinetics of abatacept [Time frame: days +30, +60, +90, 1 year, 1.5 years, and 2 years post-transplant]
- Incidence of acute graft-versus-host disease (GVHD) [Time frame: 1 year post-transplant]
- Incidence of chronic graft-versus-host disease (GVHD) [Time frame: 2 years post-transplant]
- Immune reconstitution [Time frame: days +30, +60, +90, 1 year, 1.5 years, and 2 years post-transplant]
Eligibility criteria
Inclusion criteria
- Nonmalignant disorder requiring bone marrow transplant including bone marrow failure syndromes, metabolic disorders, immunologic disorders, or hemoglobinopathy
- For patients with sickle cell disease, must have one of the following severe manifestations:
- Overt or silent stroke or persistently elevated transcranial doppler velocities despite transfusion therapy
- Recurrent acute chest syndrome with significant respiratory compromise each time
- Sickle nephropathy
- Recurrent admissions for vaso-occlusive episodes resulting in prolonged opioid use and poor quality of life with interrupted school attendance activity
- Red cell alloimmunization with the need for chronic transfusions
- Recurrent osteonecrosis or multiple joint involvement from avascular necrosis
- Patients with sickle cell disease must have hemoglobin S < 30% within 30 days prior to beginning alemtuzumab
- Age </= 20.99 years at the time of enrollment
- Performance score >/= 50
- Left ventricular ejection fraction > 40% or left ventricular shortening fraction > 26% by echocardiogram
- DLCO > 40% (corrected for hemoglobin) or pulse oximetry with a baseline O2 saturation of >/= 90% on room air if too young to perform PFTs
- Serum creatinine </= 1.5x upper limit of normal for age and/or GFR > 70 mL/min/1.73m2
- Direct bilirubin < 2x upper limit of normal for age
- ALT and AST < 5x upper limit of normal for age
- Participants who have or are receiving >/= 8 packed red blood cell transfusions for >/= 1 year or >/= 20 packed red blood cell transfusions (lifetime cumulative) will undergo liver MRI for estimation of hepatic iron content.
1\. Liver biopsy is indicated for hepatic iron content >/= 7mg Fe/mg liver dry weight by liver MRI. Histologic examination of the liver must document for the absence of cirrhosis, bridging fibrosis, and active hepatitis
- Female subjects of childbearing potential, must agree to practice 2 methods of contraception at the same time from the time of signing of informed consent through 12 months post transplant. Male subjects must agree to practice effective barrier contraception or practice true abstinence from the time of signing informed consent through 12 months post transplant.
- Written informed consent must be obtained from all recipients in accordance with the guidelines of the institution's Human Studies Committee.
Exclusion criteria
- Patients who have an HLA-identical sibling who is able and willing to donate bone marrow
- Patients with cirrhosis or established bridging fibrosis of the liver or active hepatitis
- Uncontrolled bacterial, viral, or fungal infection within 6 weeks prior to enrollment
- Evidence of HIV infection or known HIV positive serology
- Patients who have received a previous stem cell transplant
- Patients who have received an investigational drug or device or off-label use of a drug or device within 3 months of enrollment
- Females who are pregnant or breast feeding
- Patients with active autoimmune disease (e.g. sarcoidosis, lupus, scleroderma)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 4 centers
- Yale School of Medicine — New Haven
- Nemours Children's Health — Wilmington
- Helen DeVos Children's Hospital — Grand Rapids
- Washington University School of Medicine — St Louis
Publications
- Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020 Aug 25;4(16):3894-3899. doi: 10.1182/bloodadvances.2020002236. PMID 32813873
Identifiers
NCT: NCT03128996 · 201611172